Although PSMA-targeted RPT is promising and fraught with fewer adverse events compared to the conventional cytotoxic therapies, radiation exposure to normal organs can result in xerostomia or other off-target effects16–18,59,60. This evidence concerns the gene FOLH1 and xerostomia.